How “cloud-ready” is your BioPharmaceutical organization?

A cloud-only approach to BioPharmaceutical lifecycle management brings a whole host of benefits. With cloud-based ELNs expected to represent 75% of the total install base by 2028i, cloud adoption is becoming crucial to success.??

We’re reaching a tipping point, where many software vendors provide new features only to the cloud and offer only critical updates for their on-premise offering.?

The wide-ranging benefits of using cloud infrastructure for BioPharmaceutical lifecycle management include:??

1. Peace of mind with automated disaster recovery, backups and upgrades?
2. Ease of use with simple provisioning of test/sandbox environments as needed, as well as more streamlined deployments?
3. Flexibility with systems designed for high availability and resilience, with scalability built-in?

?

However, according to research shared by?Scientific Computing World, only 20% of non-ELN users feel comfortable implementing a completely electronic environment for the protection of their intellectual property. But why the hesitance??

Despite the prevalence of cloud computing in everyday life, it’s not surprising that the thought of moving BioPharmaceutical lifecycle management data to the cloud can cause concern, especially for organizations working in regulated environments with critical data. Three common concerns are cost, loss of control and data security.???

?

Peace of mind built-in?

Moving to the cloud does – of course – involve a different cost structure and takes the responsibility away from internal resources. It eliminates the need to maintain on-premise systems and servers so IT teams can be redeployed to other projects. The cloud and SaaS subscriptions replace this burden, often with a set monthly/annual cost, making budgeting and resource allocation straightforward.??

The extensive security in place with established cloud providers such as AWS, Azure or GCP means that systems are as resilient and secure – if not more so – than on-premise installations. For example, the IDBS Cloud is deployed in an N+1 architecture, meaning that servers run across geographically diverse data centers, ensuring there is a backup in place should any single system component fail. Automated disaster recovery, backups, upgrades and patches are included in the cloud subscription.?

?

The future is cloud?

Cloud-based deployments can unlock the potential of AI (artificial intelligence) and ML (machine learning), which is dependent on having “good” data: data that is accurate, complete, reusable and accessible. With this data, AI and ML can drive efficiency gains with in-silico modeling, experimental prediction and improved decision-making. Some companies are already using AI and ML to re-analyze historical “good” data to discover new insights, that might lead to potential new drugs or new applications of existing drugs.??

AI and ML are already reshaping the BioPharmaceutical industry, but only with “good” data will these tools be able to power drug discovery, streamline processes, reduce costs and accelerate time to market.?

?

Make the move to the cloud with ease?

Hopefully, we have convinced you that moving your BioPharmaceutical lifecycle management system to the cloud is a no-brainer. But to fully benefit from the move and to maximize its potential, upgrading your tools at the same time would also be very wise. Modern solutions include digital workflows designed to create a persistent, dynamic data backbone throughout the BioPharma lifecycle. This provides a solid foundation for analytics, accelerated time-to-insight and future?digital twin?and in silico modeling.?

One example is?IDBS Polar, a BioPharma Lifecycle Management (BPLM) platform for data capture, process execution, advanced analysis, data visualization and reporting across the drug development lifecycle. Combining experimental- and model-based outcomes eliminates manual processes and makes digital workflows more efficient and seamless.?

?

So what are you waiting for? Are you ready to move to cloud-only BioPharmaceutical lifecycle management? If not, why not?

If you haven’t already moved to the cloud, tell us how cloud-ready your BioPharmaceutical organization is by using the following phrases in the comments:?

1. Ready to go?

2. Researching my options?

3. Still using on-premise?

4. Need help!?

?

Follow us to learn how cloud-based BioPharma lifecycle management can transform your business.

[i] Top-Down Analytics, Laboratory Data Management Software Market Forecast 2023-2028, published July 2023.